<DOC>
	<DOCNO>NCT00390338</DOCNO>
	<brief_summary>RATIONALE : Vaccines make person 's dendritic cell mixed tumor peptide protein may help body build effective immune response kill tumor cell . Infusing vaccine directly lymphatic system may cause strong immune response kill tumor cell . PURPOSE : This randomized phase I trial study side effect best dose two dendritic cell vaccine treat patient stage III stage IV melanoma .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Stage III Stage IV Melanoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare safety intralymphatic autologous type-1-polarized dendritic cell vaccine vs autologous mature dendritic cell vaccine load antigenic peptide proteins patient stage III IV melanoma . Secondary - Determine peripheral blood CD8+ CD4+ T-cell responses HLA-presented melanoma epitopes autologous tumor cell use interferon gamma interleukin-5 ELISPOT assay . - Compare delayed-type hypersensitivity ( DTH ) responses regimens DTH autologous tumor lysates patient . - Compare DTH response keyhole limpet hemocyanin pan-DR epitope ( PADRE ) patient . - Correlate treatment-associated change immune response clinical outcome . OUTLINE : This randomize , open-label , dose-escalation study . Patients randomize 1 2 formulation dendritic cell ( DC ) vaccine . - Arm I : Patients receive intralymphatic autologous type-1-polarized ( interleukin-1-beta , tumor necrosis factor [ TNF ] alfa , interferon alfa , poly-I : C , interferon gamma ) DC vaccine load tumor-related peptide antigen ( gp100:209-217 [ 210M ] peptide , tyrosinase peptide , MART-1:27-35 peptide , MAGE-3/6 , EphA2 ) proteins ( keyhole limpet hemocyanin [ KLH ; first course ] pan-DR epitope [ PADRE ] [ second course ] ) every 6 hour day 1-4 week 1 6 . - Arm II : Patients receive intralymphatic autologous mature ( interleukin-1-beta , TNF alfa , interleukin-6 , prostaglandin E_2 ) DC vaccine load tumor-related peptide antigens proteins arm I every 6 hour day 1-4 week 1 6 . Patients achieve complete response receive 2 course treatment ( 3 month apart ) . Patients achieve partial response receive 10 course treatment ( 1 month apart ) absence disease progression unacceptable toxicity . In arm , cohorts 4-7 patient receive escalate dos DC vaccine maximum tolerate dose ( MTD ) determine . The MTD define dose 1 7 patient experience dose-limiting toxicity . Blood sample obtain baseline periodically treatment . Samples examine immunoenzyme technique immunologic measurement . After completion study therapy , patient follow periodically 10½ year annually thereafter . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Pathologically confirm stage III IVA ( M1a ) melanoma Recurrent inoperable disease Any tumor thickness number lymph node involve Asymptomatic cutaneous nodal disease allow Asymptomatic pulmonary metastatic disease ( stage IVB , M1b ) allow No advance symptomatic visceral disease , include symptomatic visceral organ involvement , disease associate increase serum lactic dehydrogenase &gt; 2.5 time upper limit normal ( stage IVC , M1c ) Standard curative palliative measure exist longer effective Sufficient number monocyte ( ≥ 20 x 10^6 ) must obtain preparation vaccine If insufficient number cell obtain first venipuncture , second venipuncture may perform ( exceed 550 mL blood within 8 week ) No brain metastasis contrastenhanced CT scan MRI Prior brain metastasis allow provide successfully treated patient asymptomatic ≥ 3 month HLAA2 positive PATIENT CHARACTERISTICS : ECOG performance status 01 Life expectancy ≥ 6 month Granulocyte count ≥ 1,500/mm³ Lymphocyte count ≥ 500/mm³ Platelet count &gt; 70,000/mm³ ( venipuncture/pheresis procedure ) Creatinine ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN Gammaglutamyl transferase ≤ 2.5 time ULN Lactic dehydrogenase ≤ 2.5 time ULN Alkaline phosphatase ≤ 2.5 time ULN Bilirubin ≤ 1.5 time ULN No active infection No sensitivity drug provide local anesthesia No pain uncontrolled oral analgesic , include opiate opiate analog No active autoimmune disease No HIV , hepatitis B , hepatitis C positivity Not pregnant nursing Fertile patient must use effective contraception Negative pregnancy test No malignancy except nonmelanoma skin cancer carcinoma situ cervix , malignancy patient continuously diseasefree ≥ 2 year PRIOR CONCURRENT THERAPY : Recovered prior surgery No radiotherapy , chemotherapy , immunotherapy within past 4 week ( 6 week nitrosoureas mitomycin C ) No antibiotic within past 7 day No systemic immunosuppressive agent , include steroid , within past 4 week Concurrent maintenance steroid adrenal insufficiency allow No concurrent anticancer investigational commercial agent therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>stage IIIA melanoma</keyword>
	<keyword>stage IIIB melanoma</keyword>
	<keyword>stage IIIC melanoma</keyword>
</DOC>